Chinese government-owned vaccine developer Sinopharma says its COVID-19 vaccine candidate has generated a 100 percent antibody response in patients who were given two medium doses 28 days apart.
Sinopharma reported the results of its phase 1/2 placebo-controlled trial in healthy volunteers ages 18 to 59 years old who were given two low, medium or high doses of the vaccine. A total of 1,120 subjects have received two doses to date.
The company said all subjects given the vaccine produced antibodies, although it did not specify the levels of immune response in patients given two doses of the vaccine at low and medium strength. No serious adverse reactions were reported.